Customer sentiment is likely positive among investors and the medical community, driven by promising clinical trial data and FDA interactions for nomlabofusp, indicating a clear pathway to market. Patients and advocacy groups also hold positive sentiment due to the hope offered by new treatment development for a rare disease with limited options.

Focus marketing and communication efforts on highlighting patient impact and expanded access policies to resonate with the broader rare disease community.